Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2022 - 2024)

Historic Non-Current Deffered Revenue for Atara Biotherapeutics (ATRA) over the last 3 years, with Q3 2024 value amounting to $470000.0.

  • Atara Biotherapeutics' Non-Current Deffered Revenue fell 9936.43% to $470000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $470000.0, marking a year-over-year decrease of 9936.43%. This contributed to the annual value of $37.6 million for FY2023, which is 5121.82% down from last year.
  • As of Q3 2024, Atara Biotherapeutics' Non-Current Deffered Revenue stood at $470000.0, which was down 9936.43% from $567000.0 recorded in Q2 2024.
  • Over the past 5 years, Atara Biotherapeutics' Non-Current Deffered Revenue peaked at $78.0 million during Q1 2023, and registered a low of $470000.0 during Q3 2024.
  • Its 3-year average for Non-Current Deffered Revenue is $43.1 million, with a median of $43.3 million in 2022.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 7461.62% in 2023, then tumbled by 9936.43% in 2024.
  • Over the past 3 years, Atara Biotherapeutics' Non-Current Deffered Revenue (Quarter) stood at $77.0 million in 2022, then tumbled by 51.22% to $37.6 million in 2023, then crashed by 98.75% to $470000.0 in 2024.
  • Its Non-Current Deffered Revenue stands at $470000.0 for Q3 2024, versus $567000.0 for Q2 2024 and $719000.0 for Q1 2024.